Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology
|
| gptkbp:allows |
bispecific antibodies
multispecific_antibodies |
| gptkbp:appliesTo |
autoimmune diseases
cancer treatment infectious diseases |
| gptkbp:developedBy |
gptkb:Xencor
|
| gptkbp:enables |
engineered Fc domains
|
| gptkbp:enhances |
efficacy
|
| gptkbp:hasClient |
precision medicine
biomedical advancements |
| gptkbp:hasCollaboratedWith |
academic institutions
pharmaceutical companies |
| gptkbp:hasExhibition |
therapeutic options
|
| https://www.w3.org/2000/01/rdf-schema#label |
XmAb® technology
|
| gptkbp:improves |
pharmacokinetics
|
| gptkbp:isAimedAt |
improving patient care
|
| gptkbp:isAttendedBy |
cancer therapies
|
| gptkbp:isBasedOn |
modular protein engineering
|
| gptkbp:isChallengedBy |
next-generation therapies
|
| gptkbp:isDesignedFor |
target multiple antigens
|
| gptkbp:isEnhancedBy |
patient outcomes
drug delivery systems therapeutic efficacy clinical trial designs Fc engineering |
| gptkbp:isEvaluatedBy |
safety and efficacy
|
| gptkbp:isFacilitatedBy |
combination therapies
research collaborations |
| gptkbp:isFocusedOn |
targeted therapies
immunotherapy |
| gptkbp:isIntegratedWith |
novel targets
|
| gptkbp:isLedBy |
new treatments
|
| gptkbp:isMarketedAs |
gptkb:XmAb®_platform
|
| gptkbp:isPartOf |
Xencor's_pipeline
Xencor's_technology_portfolio |
| gptkbp:isPromotedBy |
scientific discovery
innovation in drug design |
| gptkbp:isRecognizedBy |
gptkb:FDA
|
| gptkbp:isRecognizedFor |
its versatility
its innovative approach |
| gptkbp:isSupportedBy |
clinical data
scientific research |
| gptkbp:isTargetedAt |
immune checkpoints
|
| gptkbp:isUtilizedFor |
personalized medicine
disease modification biotech_firms |
| gptkbp:isUtilizedIn |
clinical trials
therapeutic development various therapeutic areas therapeutic development processes |
| gptkbp:isVisitedBy |
gptkb:Xencor
|
| gptkbp:reduces |
immunogenicity
|
| gptkbp:translatedInto |
biopharmaceutical industry
treatment paradigms |
| gptkbp:usedIn |
therapeutic antibodies
|
| gptkbp:utilizes |
human IgG1 framework
|